

Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, CLIA, Rapid Tests), Specimen (Blood, Saliva, Urine), Application (Infectious Diseases, Endocrinology), End User (Hospitals & Clinics, Blood Banks) & Region - Global Forecast to 2028

<https://marketpublishers.com/r/I5CC95538B5EN.html>

Date: October 2023

Pages: 382

Price: US\$ 4,950.00 (Single User License)

ID: I5CC95538B5EN

Abstracts

The global immunoassay market is valued at an estimated USD 35.0 billion in 2023 and is projected to reach USD 46.7 billion by 2028, at a CAGR of 5.9% during the forecast period. Market growth is driven by factors such as the rising prevalence of chronic and infectious diseases, innovations in the systems and technologies, supportive government policies and initiatives, and increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing.

“The reagents & kits to register the largest share of the immunoassay market, by product.”

The global immunoassay market is segmented into reagents & kits and analyzers based on product. Market growth is largely driven by the repetitive use of reagents & kits for various diagnostic procedures coupled with the increase in the volume of immunoassay-based tests conducted worldwide. Moreover, the availability of better reagents & kits that offer efficient results and precision in diagnosis attributes to their growing requirement resulting in growth of the segment.

“Chemiluminescence Immunoassay segment to grow at a considerable rate among technology during the forecast period.”

The immunoassay market is segmented into ELISA, Chemiluminescence Immunoassay (CLIA), Immunofluorescence assay (IFA), rapid tests, ELISpot, western blotting, and other technologies. CLIA tests help efficiently diagnose various chronic and infectious diseases compared to other techniques such as ELISA and radioimmunoassays, owing to benefits such as sensitivity, wide dynamic range, better speed, reduced interference, and high specificity.

“Infectious diseases segment accounted for the largest share in the immunoassay market, by application.”

The global immunoassay market is segmented into infectious diseases, cardiology, endocrinology, oncology, bone & mineral disorders, autoimmune disorders, blood screening, allergy diagnostics, drug monitoring and testing, newborn screening, and other applications. The application segment of infectious diseases accounted for a considerable share in 2022, primarily due to the rapid diagnosis of infectious diseases coupled with the increasing incidence of diseases such as HIV/AIDS, malaria, hepatitis, and influenza, among others.

“Asia Pacific: The fastest-growing region in the immunoassay market.”

The global immunoassay market is segmented into five regions - North America, Europe, the Asia Pacific, the Middle East & Africa, and Latin America. The Asia Pacific region is expected to grow at the highest rate during the forecast period in the immunoassay market. The high growth in the region is due to the presence of a large target population, and rising prevalence of chronic disorders in Asian countries.

The break-up of the profile of primary participants in the immunoassay market:

By Company Type: Tier 1 - 28%, Tier 2 - 41%, and Tier 3 – 31%

By Designation: C-level - 30%, D-level - 34%, and Others - 36%

By Region: North America - 38%, Europe - 27%, Asia Pacific - 18%, Latin America – 6% and Middle East & Africa – 11%,

The key players in this market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), PerkinElmer, Inc. (US), Becton, Dickinson and

Company (US), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (US), bioMérieux (France), QIAGEN N.V. (Germany), Sysmex Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., LTD. (China), Agilent Technologies (US), Merck KGaA (Germany), Meridian Bioscience (US), Bio-Techne (US), Cellabs (Australia), Abnova Corporation (Taiwan), J. Mitra & Co. Pvt. Ltd. (India), Tosoh Corporation (Japan), Cell Sciences (US), Enzo Biochem (US), Creative Diagnostics (US), Boster Biological Technology (US), Elabscience (US), WAK-Chemie Medical GmbH (Germany), Sera Care (US), Epitope Diagnostics Inc. (US), Kamiya Biomedical Company (US), Gyros Protein Technologies (Sweden), Trivitron Healthcare (India), InBios International Inc. (India), and Maccura Biotechnology Co., Ltd. (China).

Research Coverage:

This research report categorizes the immunoassay market by product (reagents & kits and analyzers), specimen type (blood, urine, saliva, and other specimens), technology (enzyme-linked immunosorbent assays, rapid tests, chemiluminescence immunoassay, immunofluorescence assay, enzyme-linked immunospot, western blotting, and other technologies), application (infectious diseases, blood screening, oncology, endocrinology, bone and mineral disorders, autoimmune disorders, cardiology, drug monitoring and testing, allergy diagnostics, newborn screening, and other applications), end user (clinical laboratories, hospitals and clinics, research & academic laboratories, blood banks, pharmaceutical and biotechnology companies & CROs, and home care settings), and region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the immunoassay market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products offered, key strategies, acquisitions, and partnerships. New product launches and approvals, and recent developments associated with the immunoassay market. This report covers the competitive analysis of upcoming startups in the immunoassay market ecosystem.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall immunoassay market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges,

and opportunities.

The report provides insights on the following pointers:

Analysis of key drivers (incidence of chronic and infectious diseases and growing awareness about early disease diagnosis, in systems and technologies, growth in biotechnology and biopharmaceutical industries, increasing adoption of immunoassay-based POC testing and rapid testing, supportive government policies, and increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing), restraints (requirements for approval of immunoassay instruments and consumables and technical hurdles of immunoassay kits), opportunities (opportunities in emerging economies, importance of companion diagnostics, development of condition-specific biomarkers and tests, integration of microfluidics in immunoassays, and improving immunoassay diagnostic technologies), and challenges (design challenges, complexities, and quality of antibodies, dearth of skilled professionals, unfavourable reimbursement scenario, and financial hurdles faced by physicians) influencing the growth of the immunoassay market

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the immunoassay market.

Market Development: Comprehensive information about lucrative markets – the report analyses the immunoassay market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the immunoassay market

Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), and Thermo Fisher Scientific Inc. (US) among others in the immunoassay market strategies.

Contents

1 INTRODUCTION

1.1 STUDY OBJECTIVES

1.2 MARKET DEFINITION

1.3 INCLUSIONS & EXCLUSIONS

1.4 MARKET SCOPE

1.4.1 MARKETS COVERED

FIGURE 1 IMMUNOASSAY MARKET SEGMENTATION

1.4.2 REGIONS COVERED

1.4.3 YEARS CONSIDERED

1.4.4 CURRENCY CONSIDERED

1.5 STAKEHOLDERS

1.6 SUMMARY OF CHANGES

1.6.1 IMPACT OF RECESSION: IMMUNOASSAY MARKET

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA

FIGURE 2 RESEARCH DESIGN

2.1.1 SECONDARY RESEARCH

2.1.1.1 Key data from secondary sources

2.1.2 PRIMARY RESEARCH

2.1.2.1 Primary sources

2.1.2.2 Key data from primary sources

2.1.2.3 Key industry insights

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS

FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION

2.2 MARKET SIZE ESTIMATION

FIGURE 5 REVENUE SHARE ANALYSIS

FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS

FIGURE 7 TOP-DOWN APPROACH

2.3 MARKET BREAKDOWN AND DATA TRIANGULATION

FIGURE 8 DATA TRIANGULATION METHODOLOGY

2.4 MARKET SHARE ANALYSIS

2.5 STUDY ASSUMPTIONS

2.5.1 MARKET ASSUMPTIONS

2.5.2 GROWTH RATE ASSUMPTIONS

2.6 RESEARCH LIMITATIONS

2.6.1 METHODOLOGY-RELATED LIMITATIONS

2.6.2 SCOPE-RELATED LIMITATIONS

2.7 RISK ASSESSMENT

TABLE 1 RISK ASSESSMENT: IMMUNOASSAY MARKET

2.8 IMPACT OF RECESSION ON IMMUNOASSAY MARKET

3 EXECUTIVE SUMMARY

FIGURE 9 IMMUNOASSAY MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION)

FIGURE 10 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)

FIGURE 11 IMMUNOASSAY MARKET, BY SPECIMEN, 2023 VS. 2028 (USD BILLION)

FIGURE 12 IMMUNOASSAY MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION)

FIGURE 13 IMMUNOASSAY MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)

FIGURE 14 GEOGRAPHICAL SNAPSHOT: IMMUNOASSAY MARKET

4 PREMIUM INSIGHTS

4.1 IMMUNOASSAY MARKET OVERVIEW

FIGURE 15 RISING INCIDENCE OF CHRONIC DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET

4.2 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT AND COUNTRY (2022)

FIGURE 16 REAGENTS & KITS AND US DOMINATED NORTH AMERICAN IMMUNOASSAY MARKET IN 2022

4.3 GEOGRAPHICAL SNAPSHOT: IMMUNOASSAY MARKET, 2023–2028

FIGURE 17 CHINA TO WITNESS HIGHEST GROWTH RATES DURING FORECAST PERIOD

4.4 REGIONAL MIX: IMMUNOASSAY MARKET, 2021–2028

FIGURE 18 ASIA PACIFIC TO WITNESS HIGHEST CAGR DURING STUDY PERIOD

4.5 DEVELOPED VS. EMERGING ECONOMIES: IMMUNOASSAY MARKET, 2023–2028

FIGURE 19 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING

FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

FIGURE 20 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: IMMUNOASSAY MARKET

5.2.1 DRIVERS

5.2.1.1 Increasing incidence of chronic and infectious diseases

FIGURE 21 INCREASING INCIDENCES OF DIABETES (IN MILLION)

5.2.1.1.1 Growing use of immunoassays in oncology

TABLE 2 GLOBAL INCIDENCE OF MAJOR CANCERS IN MEN, 2020

TABLE 3 GLOBAL INCIDENCE OF MAJOR CANCERS IN WOMEN, 2020

5.2.1.1.2 Increasing use of immunoassays in diagnostic applications

TABLE 4 TIME REQUIRED FOR DRUG DETECTION BY URINE TESTING

5.2.1.1.3 Growing geriatric population

FIGURE 22 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (IN MILLION)

5.2.1.2 Increasing need for blood donations

5.2.1.3 Growth in biotechnology & biopharmaceutical industries

5.2.1.4 Increasing adoption of immunoassay-based POC testing and rapid testing

5.2.1.5 Supportive government regulatory policies and initiatives

5.2.1.6 Increased drug abuse and use of cannabis

5.2.2 RESTRAINTS

5.2.2.1 Stringent approval criteria for immunoassay instruments and consumables

5.2.2.2 Technical problems in immunoassay kits

5.2.3 OPPORTUNITIES

5.2.3.1 Increasing growth opportunities in emerging economies

5.2.3.2 Importance of companion diagnostics

TABLE 5 COMPANION DIAGNOSTIC ASSAYS APPROVED AND LAUNCHED, 2018–2022

5.2.3.3 Development of condition-specific biomarkers and tests

TABLE 6 NEW TESTS LAUNCHED BY KEY PLAYERS, 2019–2023

5.2.3.4 Integration of microfluidics in immunoassays

TABLE 7 LAB-ON-A-CHIP IMMUNOASSAY DEVICES/CHIPS/SYSTEMS OFFERED BY KEY PLAYERS

5.2.3.5 Improved immunoassay diagnostic technologies

5.2.4 CHALLENGES

5.2.4.1 Design challenges, complexities, and low quality of antibodies

5.2.4.2 Dearth of skilled professionals

5.2.4.3 Unfavorable reimbursement scenario

5.3 REGULATORY ANALYSIS

5.3.1 NORTH AMERICA

5.3.1.1 US

TABLE 8 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS

FIGURE 23 US: REGULATORY PROCESS FOR IVD DEVICES

5.3.1.2 Canada

FIGURE 24 CANADA: REGULATORY PROCESS FOR IVD DEVICES

5.3.2 EUROPE

TABLE 9 EUROPE: CLASSIFICATION OF IVD DEVICES

5.3.2.1 Russia

TABLE 10 RUSSIA: CLASSIFICATION OF IVD DEVICES

5.3.3 ASIA PACIFIC

5.3.3.1 Japan

FIGURE 25 JAPAN: REGULATORY PROCESS FOR IVD DEVICES

TABLE 11 JAPAN: CLASSIFICATION OF IVD REAGENTS

TABLE 12 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS

5.3.3.2 China

TABLE 13 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS

5.3.3.3 India

FIGURE 26 INDIA: REGULATORY PROCESS FOR IVD DEVICES

5.3.3.4 Indonesia

TABLE 14 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES

5.3.3.5 South Korea

TABLE 15 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS

5.3.4 LATIN AMERICA

5.3.4.1 Mexico

FIGURE 27 MEXICO: REGULATORY PROCESS FOR IVD DEVICES

TABLE 16 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS

5.3.4.2 Brazil

FIGURE 28 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES

5.3.5 MIDDLE EAST

5.3.5.1 Saudi Arabia

TABLE 17 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS

5.3.6 AFRICA

5.4 TECHNOLOGY ANALYSIS

TABLE 18 CONVENTIONAL IMMUNOASSAY METHODS AND TECHNIQUES

TABLE 19 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN IMMUNOASSAY MARKET

5.5 TRADE ANALYSIS

5.5.1 TRADE ANALYSIS FOR IMMUNOASSAY PRODUCTS

TABLE 20 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 21 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION)

5.6 PATENT ANALYSIS

5.7 VALUE CHAIN ANALYSIS

FIGURE 29 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES

5.8 SUPPLY CHAIN ANALYSIS

FIGURE 30 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES

5.9 ECOSYSTEM/MARKET MAP

FIGURE 31 ECOSYSTEM/MARKET MAP: IMMUNOASSAY MARKET

5.9.1 ROLE IN ECOSYSTEM

5.9.2 KEY PLAYERS IN IMMUNOASSAY MARKET

5.10 PORTER'S FIVE FORCES ANALYSIS

TABLE 22 PORTER'S FIVE FORCES

5.10.1 INTENSITY OF COMPETITIVE RIVALRY

5.10.2 BARGAINING POWER OF SUPPLIERS

5.10.3 BARGAINING POWER OF BUYERS

5.10.4 THREAT OF SUBSTITUTES

5.10.5 THREAT FROM NEW ENTRANTS

5.11 KEY CONFERENCES & EVENTS IN 2023–2024

TABLE 23 KEY CONFERENCES & EVENTS IN 2023–2024

5.12 PRICING ANALYSIS

TABLE 24 PRICE RANGE FOR IMMUNOASSAY PRODUCTS

5.13 KEY STAKEHOLDERS & BUYING CRITERIA

5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS

FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER

TABLE 25 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS

5.13.2 BUYING CRITERIA

FIGURE 33 KEY BUYING CRITERIA FOR TOP END USERS**TABLE 26 KEY BUYING CRITERIA, BY TOP END USER****5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES****6 IMMUNOASSAY MARKET, BY PRODUCT****6.1 INTRODUCTION****TABLE 27 IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)****6.2 REAGENTS & KITS****TABLE 28 KEY REAGENTS & KITS AVAILABLE****TABLE 29 IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY REGION, 2021–2028 (USD MILLION)****TABLE 30 IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)****6.2.1 ELISA REAGENTS & KITS**

6.2.1.1 Increased use of high-throughput screening in drug discovery programs to drive segment

TABLE 31 ELISA REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)**6.2.2 RAPID TEST REAGENTS & KITS**

6.2.2.1 High demand for rapid test reagents & kits in remote areas for preliminary screening tests to drive segment

TABLE 32 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)**6.2.3 ELISPOT REAGENTS & KITS**

6.2.3.1 High sensitivity, functionality, and adaptability of ELISpot technology to drive segment

TABLE 33 ELISPOT REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)**6.2.4 CLIA REAGENTS & KITS**

6.2.4.1 Better diagnosis and higher specificity to drive segment

TABLE 34 CLIA REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)**6.2.5 IFA REAGENTS & KITS**

6.2.5.1 Better adaptability in clinical diagnostics and medicine to drive segment

TABLE 35 IFA REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION)**6.2.6 WESTERN BLOT REAGENTS & KITS**

6.2.6.1 Western blotting reagents & kits to be considered gold standard for COVID-19

test result validation

TABLE 36 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2021–2028
(USD MILLION)

6.2.7 OTHER REAGENTS & KITS

TABLE 37 OTHER REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD
MILLION)

6.3 ANALYZERS

TABLE 38 KEY ANALYZERS AVAILABLE

TABLE 39 IMMUNOASSAY MARKET FOR ANALYZERS, BY REGION, 2021–2028
(USD MILLION)

6.3.1 IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE

TABLE 40 IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD
MILLION)

6.3.1.1 Open-ended systems

6.3.1.1.1 Better flexibility and wider availability to drive segment

TABLE 41 OPEN-ENDED SYSTEMS MARKET, BY REGION, 2021–2028 (USD
MILLION)

6.3.1.2 Closed-ended systems

6.3.1.2.1 Higher precision and better automation to drive segment

TABLE 42 CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2021–2028 (USD
MILLION)

6.3.2 IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE

TABLE 43 IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE,
2021–2028 (USD MILLION)

6.3.2.1 Rental purchase

6.3.2.1.1 Increased convenience and lack of liability to drive segment

TABLE 44 RENTAL PURCHASE MARKET, BY REGION, 2021–2028 (USD MILLION)

6.3.2.2 Outright purchase

6.3.2.2.1 Inflated cost of immunoassay testing technologies to limit market

TABLE 45 OUTRIGHT PURCHASE MARKET, BY REGION, 2021–2028 (USD
MILLION)

7 IMMUNOASSAY MARKET, BY TECHNOLOGY

7.1 INTRODUCTION

TABLE 46 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

7.2 ELISA

7.2.1 BETTER SENSITIVITY AND QUICKER RESULTS TO DRIVE MARKET

TABLE 47 KEY ELISA TECHNOLOGIES AVAILABLE

TABLE 48 IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2021–2028 (USD MILLION)

7.3 CLIA

7.3.1 GOOD SPECIFICITY, WIDE LINEAR RANGE, AND HIGH SENSITIVITY TO DRIVE MARKET

TABLE 49 IMMUNOASSAY MARKET FOR CLIA, BY REGION, 2021–2028 (USD MILLION)

7.4 IFA

7.4.1 IFA TO DIAGNOSE ANTIBODIES AND ANALYZE SMALL BIOLOGICAL AND NON-BIOLOGICAL MOLECULES

TABLE 50 IMMUNOASSAY MARKET FOR IFA, BY REGION, 2021–2028 (USD MILLION)

7.5 RAPID TESTS

7.5.1 FASTER RESULTS AND EASE OF USE TO DRIVE MARKET

TABLE 51 KEY RAPID TESTS AVAILABLE

TABLE 52 IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION, 2021–2028 (USD MILLION)

7.6 WESTERN BLOTTING

7.6.1 ABILITY TO DETECT AND CONFIRM ANTIBODIES OF RETROVIRUSES TO DRIVE MARKET

TABLE 53 WESTERN BLOTTING SYSTEMS AVAILABLE

TABLE 54 IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION, 2021–2028 (USD MILLION)

7.7 ELISPOT

7.7.1 HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY TO DRIVE MARKET

TABLE 55 IMMUNOASSAY MARKET FOR ELISPOT, BY REGION, 2021–2028 (USD MILLION)

7.8 OTHER TECHNOLOGIES

TABLE 56 IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION)

8 IMMUNOASSAY MARKET, BY SPECIMEN

8.1 INTRODUCTION

TABLE 57 IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

8.2 BLOOD

8.2.1 HIGH RELIABILITY AND ADVANCEMENTS IN HEALTHCARE SYSTEM TO DRIVE MARKET

TABLE 58 IMMUNOASSAY MARKET FOR BLOOD, BY REGION, 2021–2028 (USD

MILLION)

8.3 SALIVA

8.3.1 DEVELOPMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO DRIVE MARKET

TABLE 59 IMMUNOASSAY MARKET FOR SALIVA, BY REGION, 2021–2028 (USD MILLION)

8.4 URINE

8.4.1 INCREASING USE BY LAW ENFORCEMENT AGENCIES AND RISING PREVALENCE OF KIDNEY DISEASES TO DRIVE MARKET

TABLE 60 IMMUNOASSAY MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION)

8.5 OTHER SPECIMENS

TABLE 61 IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION, 2021–2028 (USD MILLION)

9 IMMUNOASSAY MARKET, BY APPLICATION

9.1 INTRODUCTION

TABLE 62 IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

9.2 INFECTIOUS DISEASES

9.2.1 RISING PREVALENCE OF CHRONIC INFECTIOUS DISEASES TO DRIVE MARKET

TABLE 63 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)

9.3 ENDOCRINOLOGY

9.3.1 RISING INCIDENCE OF DIABETES TO DRIVE MARKET

TABLE 64 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION)

9.4 CARDIOLOGY

9.4.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO DRIVE MARKET

TABLE 65 KEY PRODUCTS FOR CARDIOLOGY APPLICATIONS

TABLE 66 IMMUNOASSAY MARKET FOR CARDIOLOGY, BY REGION, 2021–2028 (USD MILLION)

9.5 AUTOIMMUNE DISORDERS

9.5.1 HIGH INCIDENCE OF CHRONIC DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET

TABLE 67 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2021–2028 (USD MILLION)

9.6 ALLERGY DIAGNOSTICS

9.6.1 GROWING PREVALENCE OF ALLERGIES TO DRIVE MARKET
TABLE 68 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION,
2021–2028 (USD MILLION)

9.7 ONCOLOGY

9.7.1 RISING BURDEN OF CANCER AND GROWING EMPHASIS ON EARLY
DETECTION TO DRIVE MARKET

TABLE 69 INCREASING INCIDENCE OF CANCER, BY REGION, 2021 VS. 2030 VS.
2040 (MILLION)

TABLE 70 IMMUNOASSAY MARKET FOR ONCOLOGY, BY REGION, 2021–2028
(USD MILLION)

9.8 BONE & MINERAL DISORDERS

9.8.1 INCREASING PREVALENCE OF BONE DISEASES TO DRIVE MARKET
TABLE 71 KEY PRODUCTS FOR BONE & MINERAL DISORDERS

TABLE 72 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY
REGION, 2021–2028 (USD MILLION)

9.9 DRUG MONITORING AND TESTING

9.9.1 RISING DRUG ABUSE AND INCREASING ILLICIT DRUG CONSUMPTION TO
DRIVE MARKET

TABLE 73 KEY PRODUCTS FOR DRUG MONITORING

TABLE 74 KEY IMMUNOASSAY PRODUCTS FOR DRUG TESTING

TABLE 75 IMMUNOASSAY MARKET FOR DRUG MONITORING AND TESTING, BY
REGION, 2021–2028 (USD MILLION)

9.10 BLOOD SCREENING

9.10.1 RISING NUMBER OF BLOOD DONATIONS TO DRIVE MARKET

TABLE 76 IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY REGION,
2021–2028 (USD MILLION)

9.11 NEWBORN SCREENING

9.11.1 TECHNOLOGICAL ADVANCEMENTS AND INCREASED GOVERNMENT
SUPPORT TO DRIVE MARKET

TABLE 77 KEY PRODUCTS FOR NEWBORN SCREENING

TABLE 78 IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY REGION,
2021–2028 (USD MILLION)

9.12 OTHER APPLICATIONS

TABLE 79 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION,
2021–2028 (USD MILLION)

10 IMMUNOASSAY MARKET, BY END USER

10.1 INTRODUCTION

TABLE 80 IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

10.2 HOSPITALS & CLINICS

10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUME TO DRIVE MARKET

TABLE 81 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021–2028 (USD MILLION)

10.3 CLINICAL LABORATORIES

10.3.1 INCREASING NUMBER OF ACCREDITED LABORATORIES TO DRIVE MARKET

TABLE 82 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION)

10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS

10.4.1 GROWING DRUG DISCOVERY AND INCREASING R&D INVESTMENTS TO DRIVE MARKET

TABLE 83 IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)

10.5 HOME CARE SETTINGS

10.5.1 RISING UTILIZATION OF POC DIAGNOSTICS AND AT-HOME ANTIGEN DIAGNOSIS TO DRIVE MARKET

TABLE 84 IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION, 2021–2028 (USD MILLION)

10.6 BLOOD BANKS

10.6.1 RISING DEMAND FOR BLOOD AND INCREASING NUMBER OF ACCIDENTS TO DRIVE MARKET

TABLE 85 IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION, 2021–2028 (USD MILLION)

10.7 RESEARCH & ACADEMIC LABORATORIES

10.7.1 RISING NUMBER OF MEDICAL COLLEGES AND UNIVERSITIES TO DRIVE MARKET

TABLE 86 IMMUNOASSAY MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION)

11 IMMUNOASSAY MARKET, BY REGION

11.1 INTRODUCTION

TABLE 87 IMMUNOASSAY MARKET, BY REGION, 2021–2028 (USD MILLION)

11.2 NORTH AMERICA

FIGURE 34 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT**TABLE 88 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)****TABLE 89 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)****TABLE 90 NORTH AMERICA: IMMUNOASSAY ASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)****TABLE 91 NORTH AMERICA: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)****TABLE 92 NORTH AMERICA: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)****TABLE 93 NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)****TABLE 94 NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)****TABLE 95 NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)****TABLE 96 NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)****11.2.1 NORTH AMERICA: RECESSION IMPACT****11.2.2 US**

11.2.2.1 High healthcare expenditure and growth in geriatric population to drive market

TABLE 97 US: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)**TABLE 98 US: IMMUNOASSAY ASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)****TABLE 99 US: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)****TABLE 100 US: IMMUNOASSAY ASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)****TABLE 101 US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)****TABLE 102 US: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)****TABLE 103 US: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)****TABLE 104 US: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)****11.2.3 CANADA**

11.2.3.1 Increasing government support and rising incidence of chronic diseases to drive market

TABLE 105 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 106 CANADA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 107 CANADA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 108 CANADA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 109 CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 110 CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 111 CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 112 CANADA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3 EUROPE

TABLE 113 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 114 EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 115 EUROPE: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 116 EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 117 EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 118 EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 119 EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 120 EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 121 EUROPE: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.1 EUROPE: RECESSION IMPACT

11.3.2 GERMANY

11.3.2.1 Germany to dominate European immunoassay market during forecast period
TABLE 122 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 123 GERMANY: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 124 GERMANY: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 125 GERMANY: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 126 GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 127 GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 128 GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 129 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.3 ITALY

11.3.3.1 Growing geriatric population and increasing support for research to drive market

TABLE 130 ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 131 ITALY: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 132 ITALY: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 133 ITALY: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 134 ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 135 ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 136 ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 137 ITALY: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.4 FRANCE

11.3.4.1 Rising use of POC testing and favorable reimbursement policies to drive market

TABLE 138 FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 139 FRANCE: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 140 FRANCE: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 141 FRANCE: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 142 FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 143 FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 144 FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 145 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.5 SPAIN

11.3.5.1 Increasing adoption of technologically advanced immunoassay systems to drive market

TABLE 146 SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 147 SPAIN: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 148 SPAIN: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 149 SPAIN: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 150 SPAIN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 151 SPAIN: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 152 SPAIN: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 153 SPAIN: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.6 UK

11.3.6.1 Government support for disease diagnostics and favorable investment scenario to drive market

TABLE 154 UK: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD

MILLION)

TABLE 155 UK: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 156 UK: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 157 UK: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 158 UK: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 159 UK: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 160 UK: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 161 UK: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.7 RUSSIA

11.3.7.1 Lack of reimbursement and delays in approval to limit market

TABLE 162 RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 163 RUSSIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 164 RUSSIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 165 RUSSIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 166 RUSSIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 167 RUSSIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 168 RUSSIA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 169 RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.8 REST OF EUROPE

TABLE 170 REST OF EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 171 REST OF EUROPE: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 172 REST OF EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY

TYPE, 2021–2028 (USD MILLION)

TABLE 173 REST OF EUROPE: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 174 REST OF EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 175 REST OF EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 176 REST OF EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 177 REST OF EUROPE: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4 ASIA PACIFIC

FIGURE 35 ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT

TABLE 178 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 179 ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 180 ASIA PACIFIC: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 181 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 182 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 183 ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 184 ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 185 ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 186 ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.1 ASIA PACIFIC: RECESSION IMPACT

11.4.2 JAPAN

11.4.2.1 Increasing investments in healthcare technologies and research activities to drive market

TABLE 187 JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 188 JAPAN: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 189 JAPAN: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 190 JAPAN: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 191 JAPAN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 192 JAPAN: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 193 JAPAN: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 194 JAPAN: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.3 CHINA

11.4.3.1 Increasing government investment and rising geriatric population to drive market

TABLE 195 CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 196 CHINA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 197 CHINA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 198 CHINA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 199 CHINA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 200 CHINA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 201 CHINA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 202 CHINA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.4 INDIA

11.4.4.1 Growing medical tourism and healthcare infrastructure to drive market

TABLE 203 INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 204 INDIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 205 INDIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 206 INDIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 207 INDIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 208 INDIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 209 INDIA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 210 INDIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.5 AUSTRALIA

11.4.5.1 Increasing incidence of cancer and rising blood donations to drive market

TABLE 211 AUSTRALIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 212 AUSTRALIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 213 AUSTRALIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 214 AUSTRALIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 215 AUSTRALIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 216 AUSTRALIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 217 AUSTRALIA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 218 AUSTRALIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.6 SOUTH KOREA

11.4.6.1 Rising healthcare spending and investments in research to drive market

TABLE 219 SOUTH KOREA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 220 SOUTH KOREA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 221 SOUTH KOREA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 222 SOUTH KOREA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 223 SOUTH KOREA: IMMUNOASSAY MARKET, BY TECHNOLOGY,

2021–2028 (USD MILLION)

TABLE 224 SOUTH KOREA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 225 SOUTH KOREA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 226 SOUTH KOREA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.7 INDONESIA

11.4.7.1 Increasing geriatric population and favorable government healthcare policies to drive market

TABLE 227 INDONESIA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 228 INDONESIA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 229 INDONESIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 230 INDONESIA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 231 INDONESIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 232 INDONESIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 233 INDONESIA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 234 INDONESIA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.8 REST OF ASIA PACIFIC

TABLE 235 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 236 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 237 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 238 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 239 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 240 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 241 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 242 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.5 LATIN AMERICA

TABLE 243 LATIN AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 244 LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 245 LATIN AMERICA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 246 LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 247 LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 248 LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 249 LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 250 LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 251 LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.5.1 LATIN AMERICA: RECESSION IMPACT

11.5.2 BRAZIL

11.5.2.1 Brazil commanded largest share in Latin American immunoassay market in 2022

TABLE 252 BRAZIL: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 253 BRAZIL: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 254 BRAZIL: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 255 BRAZIL: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 256 BRAZIL: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 257 BRAZIL: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 258 BRAZIL: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 259 BRAZIL: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.5.3 MEXICO

11.5.3.1 Increasing geriatric population and rising medical tourism to drive market

TABLE 260 MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 261 MEXICO: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 262 MEXICO: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 263 MEXICO: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 264 MEXICO: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 265 MEXICO: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 266 MEXICO: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 267 MEXICO: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.5.4 REST OF LATIN AMERICA

TABLE 268 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 269 REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 270 REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 271 REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 272 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 273 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 274 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 275 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.6 MIDDLE EAST & AFRICA

11.6.1 LACK OF SKILLED LAB PERSONNEL AND UNFAVORABLE REIMBURSEMENT POLICIES TO LIMIT GROWTH

11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

TABLE 276 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 277 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR REAGENTS & KITS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 278 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY TYPE, 2021–2028 (USD MILLION)

TABLE 279 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ANALYZERS, BY PURCHASE MODE, 2021–2028 (USD MILLION)

TABLE 280 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 281 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2021–2028 (USD MILLION)

TABLE 282 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 283 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW

12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN

12.2.1 OVERVIEW OF KEY STRATEGIES ADOPTED BY MAJOR PLAYERS

TABLE 284 OVERVIEW OF MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOASSAY MARKET

12.3 REVENUE ANALYSIS

FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS

12.4 MARKET SHARE ANALYSIS

TABLE 285 DEGREE OF COMPETITION IN IMMUNOASSAY MARKET

FIGURE 37 IMMUNOASSAY MARKET SHARE, BY KEY PLAYER (2022)

12.5 COMPANY EVALUATION MATRIX

12.5.1 STARS

12.5.2 EMERGING LEADERS

12.5.3 PERVASIVE PLAYERS

12.5.4 PARTICIPANTS

FIGURE 38 COMPANY EVALUATION MATRIX, 2022

- 12.5.5 COMPANY FOOTPRINT
- TABLE 286 OVERALL FOOTPRINT
- TABLE 287 PRODUCT FOOTPRINT
- TABLE 288 REGIONAL FOOTPRINT
- 12.6 START-UP/SME EVALUATION MATRIX
 - 12.6.1 PROGRESSIVE COMPANIES
 - 12.6.2 RESPONSIVE COMPANIES
 - 12.6.3 DYNAMIC COMPANIES
 - 12.6.4 STARTING BLOCKS
- FIGURE 39 START-UP/SME EVALUATION MATRIX, 2022
- 12.6.5 COMPETITIVE BENCHMARKING
- TABLE 289 KEY START-UPS/SMES IN IMMUNOASSAY MARKET
- 12.7 COMPETITIVE SCENARIOS AND TRENDS
 - 12.7.1 KEY PRODUCT LAUNCHES AND APPROVALS
- TABLE 290 KEY PRODUCT LAUNCHES AND APPROVALS, JANUARY 2020–SEPTEMBER 2023
- 12.7.2 KEY DEALS
- TABLE 291 KEY DEALS, JANUARY 2020–SEPTEMBER 2023
- 12.7.3 OTHER KEY DEVELOPMENTS
- TABLE 292 OTHER KEY DEVELOPMENTS, JANUARY 2022–SEPTEMBER 2023

13 COMPANY PROFILES

13.1 KEY PLAYERS

(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*

- 13.1.1 ABBOTT LABORATORIES
 - TABLE 293 ABBOTT LABORATORIES: COMPANY OVERVIEW
 - FIGURE 40 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
- 13.1.2 F. HOFFMANN-LA ROCHE LTD.
 - TABLE 294 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
 - FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
- 13.1.3 SIEMENS HEALTHINEERS AG
 - TABLE 295 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
 - FIGURE 42 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
- 13.1.4 DANAHER CORPORATION
 - TABLE 296 DANAHER CORPORATION: COMPANY OVERVIEW
 - FIGURE 43 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)

13.1.5 THERMO FISHER SCIENTIFIC INC.

TABLE 297 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW

FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)

13.1.6 REVVITY

TABLE 298 REVVITY: COMPANY OVERVIEW

FIGURE 45 REVVITY: COMPANY SNAPSHOT (2022)

13.1.7 BECTON, DICKINSON AND COMPANY

TABLE 299 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW

FIGURE 46 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)

13.1.8 DIASORIN S.P.A.

TABLE 300 DIASORIN S.P.A.: COMPANY OVERVIEW

FIGURE 47 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)

13.1.9 BIO-RAD LABORATORIES, INC.

TABLE 301 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW

FIGURE 48 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)

13.1.10 QUIDELORTHO CORPORATION

TABLE 302 QUIDELORTHO CORPORATION: COMPANY OVERVIEW

FIGURE 49 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)

13.1.11 BIOM?RIEUX

TABLE 303 BIOM?RIEUX: COMPANY OVERVIEW

FIGURE 50 BIOM?RIEUX: COMPANY SNAPSHOT (2022)

13.1.12 QIAGEN N.V.

TABLE 304 QIAGEN N.V.: COMPANY OVERVIEW

FIGURE 51 QIAGEN N.V.: COMPANY SNAPSHOT (2022)

13.1.13 SYSMEX CORPORATION

TABLE 305 SYSMEX CORPORATION: COMPANY OVERVIEW

FIGURE 52 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022)

13.1.14 AGILENT TECHNOLOGIES, INC.

TABLE 306 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW

FIGURE 53 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)

13.1.15 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.

TABLE 307 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.:
COMPANY OVERVIEW

FIGURE 54 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.:
COMPANY SNAPSHOT (2022)

13.2 OTHER PLAYERS

13.2.1 MERCK KGAA

13.2.2 MERIDIAN BIOSCIENCE

13.2.3 BIO-TECHNE

- 13.2.4 CELLABS
- 13.2.5 ABNOVA CORPORATION
- 13.2.6 J. MITRA & CO. PVT. LTD.
- 13.2.7 TOSOH CORPORATION (TOSOH BIOSCIENCE)
- 13.2.8 CELL SCIENCES
- 13.2.9 ENZO BIOCHEM
- 13.2.10 CREATIVE DIAGNOSTICS
- 13.2.11 BOSTER BIOLOGICAL TECHNOLOGY
- 13.2.12 ELABSCIENCE
- 13.2.13 WAK-CHEMIE MEDICAL
- 13.2.14 SERACARE LIFESCIENCES INC.
- 13.2.15 EPITOPE DIAGNOSTICS
- 13.2.16 KAMIYA BIOMEDICAL COMPANY
- 13.2.17 GYROS PROTEIN TECHNOLOGIES
- 13.2.18 TRIVITRON HEALTHCARE
- 13.2.19 INBIOS INTERNATIONAL, INC.
- 13.2.20 MACCURA BIOTECHNOLOGY CO., LTD.

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

14 APPENDIX

- 14.1 DISCUSSION GUIDE
- 14.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL
- 14.3 CUSTOMIZATION OPTIONS
- 14.4 RELATED REPORTS
- 14.5 AUTHOR DETAILS

I would like to order

Product name: Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, CLIA, Rapid Tests), Specimen (Blood, Saliva, Urine), Application (Infectious Diseases, Endocrinology), End User (Hospitals & Clinics, Blood Banks) & Region - Global Forecast to 2028

Product link: <https://marketpublishers.com/r/I5CC95538B5EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I5CC95538B5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970